Next Generation Nootropics: What Actually Comes After Modafinil
Next Generation Nootropics: What Actually Comes After Modafinil is not a hunt for one stronger smart pill. The research is splitting into four tracks: targeted wakefulness, temporary plasticity, brain-energy support and responsive devices.
Four different futures.
The “next modafinil” may not look like modafinil at all. Each track attacks a different limit on human performance.
Orexin agonists
Target the brain’s wake-stability system instead of broadly raising stimulant signals.
CLOSEST TO MARKETPsychoplastogens
Aim to open a temporary learning window with little or no hallucinogenic effect.
EARLY RESEARCHBrain energy
Support the fuel system behind attention, especially under fatigue or stress.
HUMAN DATA, MIXEDClosed-loop devices
Measure brain state and respond with precisely timed stimulation.
PROMISING, EXPERIMENTALOrexin could change wakefulness.
Modafinil keeps people awake, but its cognitive effects in healthy, rested adults are smaller than the mythology suggests. It helps you stay at the desk. It does not turn an average brain into a supercomputer.
Orexin agonists take a more targeted route. Orexin is part of the system that stabilises wakefulness. People with narcolepsy type 1 have lost most of the cells that produce it.
Oveporexton, previously TAK-861, is designed to restore that missing signal. Takeda reports that both pivotal Phase 3 studies met all primary and secondary endpoints. The FDA has accepted the application and granted Priority Review.
The tested population has a specific orexin deficit. Someone with normal orexin signalling may see a smaller benefit, no benefit, or a different side-effect profile. Reported common adverse events in the Phase 3 programme included insomnia and urinary urgency or frequency.
Not every exciting molecule is equally real.
Treat evidence level as a risk dial. A mechanism is not a clinical result, and a mouse result is not a human memory drug.
Oveporexton: Phase 3 complete, endpoints met, FDA Priority Review for narcolepsy type 1.
STRONGESTCreatine: reviews show possible cognitive benefits, with effects varying across studies and conditions.
REAL DATAZatolmilast: encouraging early results did not translate into a successful Phase 3 outcome.
CAUTIONTabernanthalog and 5-Br-DMT: interesting plasticity signals, no human cognitive proof.
EARLYDihexa, 9-Me-BC and many grey-market “research” products: inadequate human safety and dosing evidence.
HIGHEST RISKPlasticity and energy.
One track tries to make learning easier. The other tries to keep the brain supplied when conditions are poor.
Psychoplastogens
Psilocybin, LSD and DMT appear to open temporary periods of increased neural plasticity. Researchers are now testing compounds designed to retain the plasticity effect with weaker or absent hallucinations.
Tabernanthalog and 5-Br-DMT have produced interesting structural and behavioural changes in animals. That does not yet prove better human judgement or memory.
Read the tabernanthalog study →Brain-energy support
The brain uses the same creatine-based energy system that made creatine famous in sport. A 2024 review found possible benefits in some areas of cognition, although results varied.
A separate sleep-deprivation study found that a large experimental dose reduced cognitive decline. That is a research clue, not a dosing recommendation.
Read the creatine review →The grey market moves faster than the evidence.
Semax and Selank
Human studies exist, but evidence and regulatory status vary. Online supply often comes through unregulated channels.
Big claims, tiny evidence base
Human safety data is close to nonexistent despite dramatic marketing about neural connections.
Dependence risk
Short-term anxiety relief can become tolerance, dependence and severe withdrawal with repeated use.
Mechanism over proof
The dopamine-support story is interesting. Reliable human safety and efficacy evidence is not there.
Three signals to watch.
Follow regulatory records and replicated human results, not launch copy or forum excitement.
Oveporexton decision window
The FDA has set a third-quarter target date. Any approval would be for narcolepsy type 1, not healthy-user enhancement.
FDA peptide committee
Semax, Epitalon and emideltide are on the agenda. Committee recommendations are advisory and non-binding.
Closed-loop systems
Responsive stimulation may eventually deliver more precision than a drug circulating for hours.
Follow human evidence. Ignore miracle claims.
The field is moving towards matching a tool to a specific biological problem. Until then, “experimental” should be read as a warning, not a benefit.
See What We Actually StockWhat nootropic users should know
Is there a replacement for modafinil yet?
Not for healthy users. Oveporexton is under FDA Priority Review for narcolepsy type 1. Approval for a diagnosed sleep disorder would not make it a general-purpose nootropic.
Are new nootropics stronger than modafinil?
There is no convincing evidence of that in healthy people. Many newer candidates target a specific deficit, so large effects in patients may shrink or disappear in healthy users.
Should I buy Semax or other peptides now?
This page does not recommend sourcing experimental compounds from grey-market suppliers. The July FDA committee is reviewing whether certain substances should be considered for compounding; its recommendations are not approvals.
Is creatine really a nootropic?
Creatine supports cellular energy in the brain as well as muscle. Reviews suggest possible cognitive benefits, particularly under demanding conditions, but results are mixed and it does not act like a stimulant.
Why do promising cognitive drugs fail?
Small early trials can exaggerate effects. Larger Phase 3 programmes use more participants and tougher endpoints, which often exposes weak or unreliable benefits.
Shane Hellmrich
Studied Health Promotion at Curtin University. Tracking modafinil and nootropic research since 2014.